GLP-1s and Desire: What We Actually Know, and What We Don't
A growing number of people in Nashville are taking semaglutide or tirzepatide — Ozempic, Wegovy, Mounjaro, Zepbound and a meaningful subset of them have noticed something change in their intimate lives.
Some have noticed desire increase. Some have noticed it decrease, sometimes substantially. Almost none of them were told anything about this possibility when the prescription was written, and almost none of them have found a clear answer when they went looking.
I want to write about this carefully, because it is genuinely current, genuinely relevant, and genuinely under-researched — and because the two dominant treatments of it online are both wrong. One says these drugs destroy your libido. The other says they improve everything about your sexual health. The actual answer, right now, is considerably less satisfying than either.
What the Research Actually Shows
Let me start with the honest summary: we do not know yet, and anyone who tells you confidently either way is ahead of the evidence.
There is a plausible mechanism for decreased desire.
An abstract presented in the Journal of Sexual Medicine in 2025 by Tveit, Simon, and Gelfand proposed a serotonergic mechanism by which GLP-1 agonists should theoretically decrease sexual desire — and, notably, offered a biopsychosocial explanation for why that effect might be camouflaged by confounding influences. Their point is subtle and worth sitting with: if a drug simultaneously reduces desire pharmacologically and improves body image and metabolic health, the two effects may partially cancel in aggregate data while being very real for individuals.
There is also a plausible mechanism for increased desire.
Weight loss, improved glycemic control, better cardiovascular function, and improved body image all support sexual function. For people whose sexual difficulties were driven by metabolic factors, these drugs may genuinely help.
The direct evidence is remarkably thin.
As summarized in a review of the current literature, the only randomized controlled trial examining GLP-1s and sexual desire used 24 lean healthy men on dulaglutide for four weeks and found no effect. That study tells us almost nothing about the population actually taking these drugs — predominantly women, predominantly with obesity, predominantly for a year or more.
Survey data runs in both directions.
A 2025 Kinsey Institute survey of 2,000 adults found that among GLP-1 users, 18% reported increased sexual desire and 16% reported decreased desire. Nearly symmetrical. The FDA adverse event database has flagged 182 cases of GLP-1-associated sexual dysfunction since 2003 — a weak signal relative to the millions of prescriptions written.
There may be a specific subgroup effect.
GoodRx's clinical summary notes a possible slightly increased risk of erectile dysfunction for men using semaglutide for weight loss without a diabetes diagnosis — while the overall risk remains small. Sexual side effects were not reported in the original clinical trials.
Why the Mechanism Is Interesting
The reason this warrants attention rather than dismissal is that GLP-1 receptors are not confined to the gut.
They are expressed throughout the brain's reward circuitry — including the nucleus accumbens and the ventral tegmental area, the same structures that govern motivation, anticipation, and the drive to pursue anything at all. This is precisely why these drugs work for appetite: they act on the wanting system, not just on satiety signaling.
The wanting system is not appetite-specific. It is the same machinery that generates sexual desire, and the same machinery that generates the motivation to pursue a hobby, a project, or a person.
A substantial number of people on these medications report a broader flattening — not just reduced food noise but reduced noise generally. Less craving for alcohol. Less compulsive shopping. And, for some, less spontaneous sexual wanting.
That is not a coincidence. It is the predictable consequence of acting on a reward system that does not specialize.
What This Means Practically
If your desire changed after starting one of these drugs, you are not imagining it.
The individual variation in response appears to be enormous, and aggregate data that shows no average effect is entirely compatible with a meaningful effect in you specifically.
Tell your prescriber.
This is a legitimate clinical observation and it deserves to be recorded. The evidence base is thin partly because these effects are not being systematically collected. Reporting it contributes to the picture and may also produce practical options — dose adjustment, timing, or a different agent.
Do not stop the medication over this without medical guidance.
These drugs are frequently treating serious metabolic conditions. The intimate dimension matters, and it is not the only thing that matters.
Distinguish between desire and capacity.
Several people I have worked with on these medications describe not a loss of enjoyment but a loss of initiation — the wanting is quieter while the capacity for pleasure is intact. That distinction matters enormously, because it means the intimate life is genuinely available; it simply needs to be entered deliberately rather than arrived at spontaneously.
This is, functionally, a shift from spontaneous to responsive desire — and as I have written about extensively, responsive desire is entirely workable once you understand it. It requires conditions rather than impulse. It requires someone to create those conditions rather than waiting for wanting to arrive.
Tell your partner what is happening.
The single most damaging version of this is the one where desire quietly changes, nobody names the medication as a possible cause, and both partners reach for relational explanations. "I started this drug and my desire has changed and it is not about you" costs one sentence and prevents months of misattribution.
The Honest Bottom Line
We do not have good data yet. The population taking these drugs is enormous and growing, the research base is small and poorly matched to that population, and the mechanism is plausible enough in both directions that confident claims are unwarranted.
What I can tell you is that if your intimate life changed when you started one of these medications, that is worth taking seriously, worth raising with your physician, and worth naming to your partner.
And it is worth knowing that a quieter wanting is not the end of an intimate life. It is a shift in how that life has to be entered.
Book a free discovery call and let's talk about how to build an intimate life that does not depend on spontaneous desire arriving first.
And if you need a way in that requires nothing from your wanting system, Coelle offers guided experiences built entirely around presence rather than impulse.
Scott Schwertly is a Nashville-based sex and intimacy coach, founder of Coelle, and co-host of Do You Feel That? with his wife Brittney. This post is educational and is not medical advice. Never adjust or discontinue a prescribed medication without consulting the prescribing physician.
Comments